Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- 26 September 2013
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (13), 1277-1279
- https://doi.org/10.1056/nejmc1309710
Abstract
To the Editor: Byrd et al. (July 4 issue)1 describe the beneficial targeting of Bruton's tyrosine kinase (BTK) with ibrutinib in relapsed chronic lymphocytic leukemia (CLL), and we note the absence of any visual deterioration in the cohort.We herein report on an 80-year-old woman with CLL who had received ibrutinib for the preceding 6 months and who had a 1-month history of deteriorating vision. Examination revealed a best corrected vision of 20/40 in each eye and bilateral cataracts of a very unusual phenotype (Figure 1). These peculiar lens opacities did not precede ibrutinib treatment, as far as we could . . .Keywords
This publication has 12 references indexed in Scilit:
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2013
- Human Cataract Mutations in EPHA2 SAM Domain Alter Receptor Stability and FunctionPLOS ONE, 2012
- The role of Eph receptors in lens function and diseaseScience China Life Sciences, 2012
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBlood, 2012
- Time-specific blockade of PDGFR with Imatinib (Glivec®) causes cataract and disruption of lens fiber cells in neonatal miceVirchows Archiv, 2010
- Cross validation of the Multiple Electrode AggregometryThrombosis and Haemostasis, 2009
- X-Linked AgammaglobulinemiaMedicine, 2006
- Incidence of age-related cataract over a 10-year intervalOphthalmology, 2002
- A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagenCurrent Biology, 1998